TRIO is dedicated to advancing translational cancer research by bringing
forward innovative and targeted therapeutic concepts into the clinical trial setting by:


Translating preclinical findings into clinical research,
Validating molecular markers and characterizing mechanisms of action,
Generating clinical hypotheses based on the underlying biology of the disease,
Assessing in vitro new agents in combination with others.
Partnering with industry in the development of novel anticancer agents,
Conducting innovative clinical research across all phases of drug development and disease sites,
Working with investigators who deliver high quality data and guarantee patient safety, and
Maintaining focus on the ultimate goal, that of improving quality of life and survival in patients with cancer.

Where does TRIO come from?

TRIO has been created following the merge of CIRG and TORI late 2005 to created a truly unique translational research organization in oncology, using the HER2 experience, from “bench to bedside“ as the backbone for the translational model we have adopted for TRIO. This new identity provides the formal link to basic research laboratories where new biologic treatments are evaluated. Based on signals seen in the preclinical setting, a targeted therapy may there be evaluated in the clinical setting either through the TORI division (early phase) and/or through the CIRG division. A Scientific Committee composed of world-renown researchers oversees the clinical development of all agents.

The TORI operations division will evaluate a targeted therapy in phase I and/or phase II trials based on signals seen in the preclinical setting. Once leading compounds are ready for larger studies, CIRG division and its proven network of committed investigators can perform these larger phase II and III trials. Operations are based in Los Angeles, USA, in Edmonton Alberta, Canada and in Paris France.


For more information on CIRG - Cancer International Research Group - activities please click here and you will be transferred to the CIRG website.
For contact detail on the TORI- Translational Oncology Research International - division please click here.